Last reviewed · How we verify
RP103
RP103 is a monoclonal antibody targeting PCSK9.
RP103 is a monoclonal antibody targeting PCSK9. Used for Hypercholesterolemia.
At a glance
| Generic name | RP103 |
|---|---|
| Also known as | Cysteamine Delayed-release Capsules, cysteamine bitartrate delayed-release capsules, PROCYSBI® |
| Sponsor | Amgen |
| Drug class | PCSK9 inhibitor |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By binding to PCSK9, RP103 reduces the amount of PCSK9 in the bloodstream, leading to increased levels of low-density lipoprotein (LDL) receptors on the liver surface, which in turn increases the clearance of LDL cholesterol from the blood.
Approved indications
- Hypercholesterolemia
Common side effects
- Injection site reactions
- Musculoskeletal pain
- Fatigue
Key clinical trials
- Effectiveness of a Bilayering Serum and Cream Containing GABA, DMAE, Cysteamine, and Bakuchiol for Skin Whitening and Anti-Aging (PHASE2)
- Use of Cysteamine in the Treatment of Cystinosis
- Cystinosis and Mitochondrial Metabolism (NA)
- A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications (NA)
- PK and PD Study of NPI-001 and Cysteamine Bitartrate (PHASE1, PHASE2)
- DFT383 in Pediatric Participants With Nephropathic Cystinosis (PHASE1, PHASE2)
- A Study to Assess TTI-0102 vs Placebo in MELAS Patients (PHASE2)
- A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RP103 CI brief — competitive landscape report
- RP103 updates RSS · CI watch RSS
- Amgen portfolio CI